Chemistry42: An AI-based platform for de novo molecular design
This platform addresses drug discovery challenges for pharmaceutical researchers by providing a tool for generating validated molecular designs, though it appears incremental as it builds on existing AI and chemistry methods.
The authors tackled the problem of de novo small molecule design by developing Chemistry42, an AI-based platform that integrates computational and medicinal chemistry methods, resulting in the generation of novel molecular structures with predefined properties validated through in vitro and in vivo studies.
Chemistry42 is a software platform for de novo small molecule design that integrates Artificial Intelligence (AI) techniques with computational and medicinal chemistry methods. Chemistry42 is unique in its ability to generate novel molecular structures with predefined properties validated through in vitro and in vivo studies. Chemistry42 is a core component of Insilico Medicine Pharma.ai drug discovery suite that also includes target discovery and multi-omics data analysis (PandaOmics) and clinical trial outcomes predictions (InClinico).